George Demetri

Supplementary Tables 1-3 from A Phase 2 Study of Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma

Gregory M. Cote, Mason Aberoumand, Edwin Choy, Lucille Sebastian et autres

Supplementary Tables 1-3

Data from A Phase 2 Study of Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma

Gregory M. Cote, Mason Aberoumand, Edwin Choy, Lucille Sebastian et autres

AbstractPurpose: Angiosarcoma and epithelioid hemangioendothelioma (EHE) are two rare vascular sarcomas with limited therapeutic options. Prior reports have shown sensitivity to microtubule-targeting agents in these histologies. We report the efficacy and safety of eribulin in these vascular sarcomas in a pooled analysis …

First-in-human clinical evaluation of ST-01156, an optimized and selective degrader of RNA-binding motif 39 (RBM39): A phase 1 study in advanced solid malignancies with a focus on RBM39-dependent cancers.

Eric Keith Rowinsky, Gregory Michael Cote, George Demetri, Robert G. Maki et autres

TPS3164 Background: ST-01156 is an orally administered agent developed to degrade RBM39, a protein target that is principally involved with splicing RNA into messenger RNA and is commonly upregulated in cancer. ST-01156 has entered phase 1 clinical trials for the treatment of …

us (code pays fourni par la source)

Efficacy of velzatinib (IDRX-42) in patients with advanced/metastatic GIST by line of therapy and circulating tumor DNA response in the phase 1/1b StrateGIST 1 trial.

Michael Charles Heinrich, C Pardo Serrano, Suzanne George, Neeltje Steeghs et autres

11520 Background: Most gastrointestinal stromal tumors (GIST) are driven by mutations in KIT or PDGFRA . Resistance to standard tyrosine kinase inhibitor (TKI) therapy is largely driven by acquisition of secondary mutations in KIT exons 13/14/17/18. Velzatinib (subject to USAN approval) is …

us, es, nl, fr, gb, jp, de (code pays fourni par la source)

Velzatinib (IDRX-42) as 1L or 2L therapy for advanced gastrointestinal stromal tumors (GISTs) by KIT mutation status: A subset analysis of the phase 1/1b StrateGIST 1 study.

Robin Lewis Jones, Neeta Somaiah, Sebastian Bauer, Michael Charles Heinrich et autres

11501 Background: Most GISTs present with activating KIT mutations (exons 9/11) initially responsive to imatinib, but many progress due to diverse KIT resistance mutations (largely in exons 13/14/17/18). Velzatinib (subject to USAN approval), a novel selective KIT inhibitor, has broad mutation coverage …

gb, us, de, es, jp, cn, kr, fr (code pays fourni par la source)

Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial

Priscilla Merriam, James J. Morrow, Emanuele Mazzola, Nicole L. Solimini et autres

While most gastrointestinal stromal tumors are driven by oncogenic mutations in KIT or PDGFRA, 10-15% exhibit functional loss of the succinate dehydrogenase (SDH) complex and genome-wide DNA hypermethylation. Excess methylation in SDH-deficient gastrointestinal stromal tumors disrupts genomic insulators, inducing aberrant expression of …

us (code pays fourni par la source)

Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study

Mrinal M. Gounder, Patrick Schöffski, Robin L. Jones, Silvia Stacchiotti et autres

Advanced tumors harboring SWI/SNF mutations are rare and aggressive. Often presenting in young patients, treatment options are limited. This phase II basket study (NCT02601950) assessed oral tazemetostat, an EZH2 inhibitor, at 800 mg twice daily (N = 129). Cohorts included malignant rhabdoid …

us, be, gb, it, ca, tw, fr (code pays fourni par la source)

Epigenetic dysregulation of metabolic programs mediates liposarcoma cell plasticity

Erica Maria Pimenta, Amanda Garza, Sabrina Yvonne Camp, Jihye Park et autres

Sarcomas are rare cancers thought to arise from aberrant mesenchymal stem cell (MSC) differentiation. Liposarcoma (LPS) is among the most commonly diagnosed sarcomas and provides insights into dysfunctional differentiation through its well- and dedifferentiated subtypes (WDLPS and DDLPS). Despite differences in histology …

us (code pays fourni par la source)

A Phase 2 Study of Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma

Gregory Michael Cote, Mason Aberoumand, E. Choy, Lucille T. Sebastian et autres

PURPOSE: Angiosarcoma and epithelioid hemangioendothelioma (EHE) are two rare vascular sarcomas with limited therapeutic options. Prior reports have shown sensitivity to microtubule-targeting agents in these histologies. We report the efficacy and safety of eribulin in these vascular sarcomas in a pooled analysis …

us, au, jp (code pays fourni par la source)